FDA
-
-
-
-
-
-
-
Phathom publishes VOQUEZNA data showing nocturnal GERD relief
-
-
-
-
-
-
-
Phathom Pharmaceuticals (PHAT) PT Raised to $12 at Goldman Sachs
-
-
-
-
-
-
-
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT)
-
-
-
-
-
-
-
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
-
322,233 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

